Open Access
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 982 - 989
Section Anticorps monoclonaux : quand les cellules de l’immunité s’en mêlent
Published online 06 January 2020
  1. Miller RA, Maloney DG, Warnke R, Levy R , Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306:517–522. [Google Scholar]
  2. Marshall MJE, Stopforth RJ, Cragg MS , Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? Front Immunoly. 2017;8:1245. [CrossRef] [Google Scholar]
  3. Cartron G, Watier H, Golay J, Solal-Celigny P , From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104:2635–2642. [Google Scholar]
  4. Taylor C, Hershman D , Shah N Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res. 2007;13:5133–5143. [CrossRef] [PubMed] [Google Scholar]
  5. Cartron G, Dacheux L, Salles G, et al., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754–758. [Google Scholar]
  6. Musolino A, Naldi N , Bortesi B Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008;26:1789–1796. [CrossRef] [PubMed] [Google Scholar]
  7. Takahashi M, Kuroki Y, Ohtsubo K, Taniguchi N , Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins. 2009;344:1387–1390. [Google Scholar]
  8. Abes R, Dutertre CA, Agnelli L, Teillaud JL , Activating and inhibitory Fcgamma receptors in immunotherapy: being the actor or being the target. Rev Clin Immunol. 2009;5:735–747. [CrossRef] [Google Scholar]
  9. Ratner M , Small biotech steers HDAC inhibitor to clinic. Nat biotechnol. 2014;32:853–854. [CrossRef] [PubMed] [Google Scholar]
  10. Mastrangeli R, Palinsky W, Bierau H , Glycoengineered antibodies: towards the next-generation of immunotherapeutics. Glycobiology. 2019;29:199–210. [CrossRef] [PubMed] [Google Scholar]
  11. Mossner E, Brunker P , Moser S Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393–4402. [Google Scholar]
  12. Yu X, Marshall MJE, Cragg MS, Crispin M , Improving antibody-based cancer therapeutics through glycan engineering. BioDrugs. 2017;31:151–166. [CrossRef] [PubMed] [Google Scholar]
  13. Sharman JP, Farber CM, Mahadevan D, et al., Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. 2017;176:412–420. [Google Scholar]
  14. Luo C, Chen S, Xu N, et al., Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties. Sci Rep. 2017;7:46347. [CrossRef] [PubMed] [Google Scholar]
  15. Wierda WG, Kipps TJ, Mayer J, et al., Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. 2010;28:1749–1755. [Google Scholar]
  16. Michaud HA, Gomard T, Gros L, et al., A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. 2010;6:e1000948. [Google Scholar]
  17. Overdijk MB, Verploegen S, Bogels M , Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. mAbs. 2015;7:311–321. [CrossRef] [PubMed] [Google Scholar]
  18. Srivastava RM, Lee SC, Andrade Filho PA, et al., Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 2013;19:1858–1872. [CrossRef] [PubMed] [Google Scholar]
  19. Borg C, Jalil A , Laderach D NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood. 2004;104:3267–3275. [Google Scholar]
  20. They L, Michaud HA, Becquart O, et al., PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody. Oncoimmunology. 2017;6:e1353857. [CrossRef] [PubMed] [Google Scholar]
  21. Gros L, Dreja H, Fiser AL, et al., Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment. J Virol. 2005;79:6272–6280. [CrossRef] [PubMed] [Google Scholar]
  22. Gros L, Pelegrin M, Michaud HA, et al., Endogenous cytotoxic T-cell response contributes to the long-term antiretroviral protection induced by a short period of antibody-based immunotherapy of neonatally infected mice. J Virol. 2008;82:1339–1349. [CrossRef] [PubMed] [Google Scholar]
  23. Nasser R, Pelegrin M, Michaud HA, et al., Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody. J Virol. 2010;84:10169–10181. [CrossRef] [PubMed] [Google Scholar]
  24. Abes R, Gelize E, Fridman WH, Teillaud JL , Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood. 2010;116:926–934. [Google Scholar]
  25. DiLillo DJ, Ravetch JV , Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. 2015;161:1035–1045. [Google Scholar]
  26. Park S, Jiang Z , Mortenson ED The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010;18:160–170. [CrossRef] [PubMed] [Google Scholar]
  27. Mortenson ED, Park S, Jiang Z, et al., Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells. Clin Cancer Res. 2013;19:1476–1486. [CrossRef] [PubMed] [Google Scholar]
  28. Nasser R, Pelegrin M , Plays M Control of regulatory T cells is necessary for vaccine-like effects of antiviral immunotherapy by monoclonal antibodies. Blood. 2013;121:1102–1111. [Google Scholar]
  29. Deligne C, Metidji A, Fridman WH, Teillaud JL , Anti-CD20 therapy induces a memory Th1 response through the IFN-gamma/IL-12 axis and prevents protumor regulatory T-cell expansion in mice. 2015;29:947–957. [Google Scholar]
  30. Ren Z, Guo J, Liao J, et al., CTLA-4 limits anti-CD20-mediated tumor regression. Clin Cancer Res. 2017;23:193–203. [CrossRef] [PubMed] [Google Scholar]
  31. Zhao T, Ren H, Wang X, et al., Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma. Oncotarget. 2015;6:27816–27831. [PubMed] [Google Scholar]
  32. Garrido G, Rabasa A, Sanchez B, et al., Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. J Immunol. 2011;187:4954–4966. [CrossRef] [PubMed] [Google Scholar]
  33. Pozzi C, Cuomo A, Spadoni I, et al., The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Nat med. 2016;22:624–631. [CrossRef] [PubMed] [Google Scholar]
  34. Singh V, Gupta D , Arora R Surface levels of CD20 determine anti-CD20 antibodies mediated cell death in vitro. PloS one. 2014;9:e111113. [CrossRef] [PubMed] [Google Scholar]
  35. Westin JR, Chu F, Zhang M, et al., Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014;15:69–77. [CrossRef] [PubMed] [Google Scholar]
  36. Kohrt HE, Colevas AD, Houot R, et al., Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest. 2014;124:2668–2682. [CrossRef] [PubMed] [Google Scholar]
  37. Kohrt HE, Houot R, Weiskopf K, et al., Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest. 2012;122:1066–1075. [CrossRef] [PubMed] [Google Scholar]
  38. Houot R, Kohrt H , CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies. Oncoimmunol. 2014;3:e941740. [CrossRef] [Google Scholar]
  39. Turaj AH, Hussain K, Cox KL, et al., Antibody tumor targeting is enhanced by CD27 agonists through myeloid recruitment. 2017;32(777–91):e6. [Google Scholar]
  40. Turaj AH, Cox KL , Penfold CA Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking. Sci Rep. 2018;8:2278. [CrossRef] [PubMed] [Google Scholar]
  41. Sockolosky JT, Dougan M , Ingram JR Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci USA. 2016;113:E2646–E2654. [CrossRef] [Google Scholar]
  42. Jones JA, Mato AR, Wierda WG, et al., Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19:65–75. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.